linjc16/ctgov huggingface dataset:
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the density of DA transporters during prolonged cocaine abuse and during withdrawal from cocaine use. This aim will test the hypothesis that DA transporters are altered by cocaine abuse and reestablished during withdrawal.

Official Title
-----------------
Human Dopamine Transported Imaging in Cocaine Abuse: 1

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Cocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cocaine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physiological changes in: heart rate and blood pressure |  |  | 
| Subjective effects of cocaine inducements and withdrawal |  |  | 
| Psychological effects |  |  | 
| Effects of investigational drug |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine dependence
McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation

Study Overview
=================
Brief Summary
-----------------
Double-lumen tube intubation is difficult, compared with single lume tube. McGrath Series 5 videolaryngoscope hase been used in difficult airway management, both in anesthetized and awake patients. But there was little information about McGrath Series 5 videolaryngoscope for double-lumen tube intubation.

Detailed Description
-----------------
In this study, the purpose was to evaluate the success rate and intubation time of McGrath Series 5 videolaryngoscope for double-lumen tube intubation in patients without predictors of difficult intubation.

Official Title
-----------------
Evaluation McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation

Conditions
-----------------
Intubation; Difficult, Intubation Complication

Intervention / Treatment
-----------------
* Device: videolaryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients thoracic surgery ASA classification 1-3 Exclusion Criteria: Emergent operation predicted difficult airway difficult ventilation limited mouth opening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| videolaryngoscope<br>The patients received videolaryngoscope for double-lumen tube intubation | Device: videolaryngoscope<br>* McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intubation time | defined as time from inserting blade to mouth to three cycles on capnograph | at intubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of successful intubation at first attempt |  | at intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
McGrath Videolaryngoscope, double-lumen tube intubation, Thoracic surgery
Neural Network to Calculate Morphology of the Cleft Palate to Reduce Cleft Lip and Palate Treatment Burden.

Study Overview
=================
Brief Summary
-----------------
This study is to develop a neural network to compute palatal three dimensional (3D) geometry by using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity for reducing cleft lip and palate treatment burden. Data of palatal casts and palatal images of cleft patients routinely treated at the University Hospital Basel will be analyzed.The collection of large data helps in developing a neural network that will allow the computation of the 3D geometry from single photographs.

Official Title
-----------------
Neural Network to Calculate Morphology of the Cleft Palate to Reduce Cleft Lip and Palate Treatment Burden.

Conditions
-----------------
Orofacial Cleft, Cleft Palate

Intervention / Treatment
-----------------
* Other: data collection of palatal casts and palatal images of cleft patients routinely treated at the institution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cleft lip and palate malformation with available routinely performed plaster cast model from palatal impressions, intraoral scans from the palate and corresponding images of the cleft palate (1970 till 2025) Exclusion Criteria: Existence of a documented rejection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3D palatal geometry | palatal cleft photographs (input) and corresponding 3D palatal geometry (output) create this 3D palatal geometry for development of image based, non-invasive palatal shape reconstruction | at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cleft Lip, Neural Network, palatal plate therapy, palatal 3D geometry, palatal shape reconstruction
Tau PET Imaging in African Americans

Study Overview
=================
Brief Summary
-----------------
The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.

Official Title
-----------------
Tau PET Imaging in African Americans

Conditions
-----------------
Cognitive Impairment

Intervention / Treatment
-----------------
* Combination Product: Tau PET scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female African Americans 30 years of age or older Subjects who have completed or are scheduled to undergo the neurological evaluation procedures described below. Exclusion Criteria: Subjects unable to lie down without moving for 20 minutes. Women who are pregnant or cannot stop breast feeding for 24 hours. Claustrophobic patients unable to tolerate the scans. Subjects with a prolonged QT interval (as demonstrated by ECG test) cannot participate in the Tau-PET scans. Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc, since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Normal control<br>Cognitively normal volunteers | Combination Product: Tau PET scan<br>* Patient will receive a dose of flutaucipir and be scanned appropriately<br>|
| Experimental: Mild Cogntive impairment<br>Person with cognitive impairment that meet Peterson Criteria | Combination Product: Tau PET scan<br>* Patient will receive a dose of flutaucipir and be scanned appropriately<br>|
| Experimental: Demented<br>Patient's that meet dementia criteria | Combination Product: Tau PET scan<br>* Patient will receive a dose of flutaucipir and be scanned appropriately<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tau positive scans | Percentage of each of the three groups with tau positive scans | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dementia, African Americans, neurological exam, Alzheimer's Disease
Application of Early Goal-directed Sedation in Patients With Severe Brain Injury

Study Overview
=================
Brief Summary
-----------------
EGDS management strategy was implemented in ICU patients with severe brain injury, the depth of sedation and GCS score were monitored, and the protective effects of EGDS strategy and standard sedation strategy on the brain of patients with severe brain injury were discussed.

Official Title
-----------------
Application of Early Goal-directed Sedation in Patients With Severe Brain Injury

Conditions
-----------------
Brain Injuries, Traumatic

Intervention / Treatment
-----------------
* Other: Early goal-directed sedation programs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of severe craniocerebral injury The GCS score is 6 to 12 points Within 12 hours of intubation The mechanical ventilation time is greater than 24 hours Obtain written consent Exclusion Criteria: Pregnant women Acute liver failure Dementia or mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group<br>No intervention was implemented | |
| Experimental: Intervention Group<br>Early goal-directed sedation programs was implemented | Other: Early goal-directed sedation programs<br>* A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Richmond Agitation-Sedation Scale |  | through study completion, an average of 2 year | 
| Mechanical ventilation time |  | through study completion, an average of 2 year | 
| length of stay in ICU |  | through study completion, an average of 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication |  | through study completion, an average of 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain Injuries, Early Goal-directed Sedation
Atomoxetine in the Treatment of Binge Eating Disorder

Study Overview
=================
Brief Summary
-----------------
The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Official Title
-----------------
Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

Conditions
-----------------
Binge-eating Disorder

Intervention / Treatment
-----------------
* Drug: atomoxetine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization Exclusion Criteria: Have concurrent symptoms of bulimia nervosa or anorexia nervosa Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures Patients who are displaying clinically significant suicidality or homicidality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: atomoxetine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.

Official Title
-----------------
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: CPT-11 and TS-1
* Drug: CPT-11, 5-FU and l-LV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed colorectal cancer Locally advanced and/or metastatic colorectal cancer Have prior chemotherapy as first line treatment No prior irinotecan administration Able to take oral medication Age 20 to 75 Performance status 0 or 1 (ECOG) WBC 3,000-12,000 / mm^3 Platelet ≥100,000 / mm^3 AST and ALT ≤ 100 IU/L Creatinine ≤ 1.2 mg/dL Bilirubin ≤ 1.5 mg/dL Exclusion Criteria: Prior radio therapy for colorectal cancer Other malignancies in the past 5 years Serious illness or medical condition

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>CPT-11 and TS-1 | Drug: CPT-11 and TS-1<br>* TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.<br>|
| Active Comparator: 2<br>CPT-11, 5-FU and l-LV | Drug: CPT-11, 5-FU and l-LV<br>* Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival |  | every course for first three courses, then every other course | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Over all survival, Response rate, Adverse event, Medical economy |  | adverse events will be collected during treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer
Evaluation of Post-Angioplasty Outcomes

Study Overview
=================
Brief Summary
-----------------
There is no hard and fast rule guiding the clinical decision between angioplasty and amputation. As such, this decision is greatly dependant on each clinician's experience and preference as to whether treatment should be conservative or aggressive. Angioplasty can help restore blood flow and long-term patency of the blood vessels can help prevent major surgeries, such as amputation which affects patient's quality of life. However, some of these patients do not benefit from angioplasty and eventually had to undergo amputation. On the other hand, there are patients that undergo amputation, but may stand to benefit from angioplasty. Hence, it is essential to identify patients that will likely benefit from angioplasty to increase limb salvage rate. Many studies performed have also concluded that before amputations are performed, surgeons should consider angioplasty procedures. Through a medical record review of patients that have undergone angioplasty to evaluate post-angioplasty outcomes, we hope to identify factors that potentially affects these outcomes. Ultimately with a better understanding of these factors and their impact on angioplasty outcomes, a predictive model or guideline can be developed to identify patients that stands to benefit from angioplasty. Such a model can help clinicians to better counsel patients on the risk and benefits, alternatives and prognosis. Patients can also make a better informed decision regarding their treatment

Official Title
-----------------
Evaluation of Post-Angioplasty Outcomes

Conditions
-----------------
Critical Limb Ischemia, Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Procedure: Lower limb angioplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted into SGH Department of Vascular Surgery, and have successfully undergone angioplasty Exclusion Criteria: Minors under age of 21

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients who have undergone LL angioplasty<br>Patients who have undergone LL angioplasty are enrolled in study for a medical records review. | Procedure: Lower limb angioplasty<br>* Patients who have undergone LL angioplasty are enrolled in study for a medical records review.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amputation Free Survival | Freedom from major limb amputation | 12 months post-op | 
| Freedom from target lesion revascularization | Freedom from any interventions to the index treated lesion | 12 months post-op | 
| Primary Patency | Patency of the treated lesion at index procedure | 12 months | 
| Wound healing rates | Healing of index wounds and whether there is any recurrence | 12 months |
The Phenomenon of Chronic Lyme; an Observational Study

Study Overview
=================
Brief Summary
-----------------
The current study is set up to chart clinically and laboratory findings in Norwegian patients with symptoms attributed by themselves or their doctor to ongoing chronic Bb infection. Objectives is to assess laboratory findings in relation to established diagnostic criteria and to form a picture of the burden of symptoms and illness perception in this group of patients. The study is essentially exploratory, and is supposed to raise rather than to test hypotheses.

Conditions
-----------------
Chronic Lyme Borreliosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptoms attributed by themselves or their doctor to ongoing chronic Bb infection Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of breast cancer.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: 111In-DAC
* Procedure: Diagnostic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients will be eligible for the study if they: Are non-pregnant, non-lactating females 18 years of age or older(must agree to use an appropriate and effective method of birth control during the study and for 2 weeks after study) Are being evaluated for a known or suspected breast tumor (must present with either a mammographic abnormality 10mm or larger or a mammographically occult but palpable abnormality of the breast) Have been previously scheduled for biopsy or surgical excision of the known or suspected tumor of the breast Have signed an informed consent form Exclusion Criteria Patients will not be eligible for this study if they: Have a history or suspicion of significant allergic reaction or anaphylaxis to any of the 111In-DAC components Have a clinically unstable medical condition or opportunistic infection, a life-threatening disease state, impaired renal or hepatic function or are immunosuppressed Are taking or have taken part in any investigational study within 30 days of start of study Have received an indium agent within 30 days of start of study Are not able to remain immobile during scanning time Have taken drugs that may damage the kidneys within 2 weeks of start of study Have abnormal laboratory test results: hemoglobin < 9.5 gms/dl, serum creatinine > 1.5 mg/100ml, alkaline phosphatase 2X the upper limit of normal Have undergone an excisional and/or needle localization biopsy within 4 days prior to start of study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 111In-DAC|nan|
|Procedure: Diagnostic|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |